Correlation Between Neuropace and Cytek Biosciences

Can any of the company-specific risk be diversified away by investing in both Neuropace and Cytek Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Cytek Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neuropace and Cytek Biosciences, you can compare the effects of market volatilities on Neuropace and Cytek Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Cytek Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Cytek Biosciences.

Diversification Opportunities for Neuropace and Cytek Biosciences

-0.72

Correlation Coefficient

Neuropace  Cytek Biosciences

Pay attention - limited upside

The 3 months correlation between Neuropace and Cytek is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Cytek Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cytek Biosciences and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Cytek Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cytek Biosciences has no effect on the direction of Neuropace i.e., Neuropace and Cytek Biosciences go up and down completely randomly.

Pair Corralation between Neuropace and Cytek Biosciences

Given the investment horizon of 90 days Neuropace is expected to under-perform the Cytek Biosciences. In addition to that, Neuropace is 1.19 times more volatile than Cytek Biosciences. It trades about -0.09 of its total potential returns per unit of risk. Cytek Biosciences is currently generating about 0.13 per unit of volatility. If you would invest  302.00  in Cytek Biosciences on May 11, 2025 and sell it today you would earn a total of  109.00  from holding Cytek Biosciences or generate 36.09% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Neuropace  vs.  Cytek Biosciences

Neuropace

Risk-Adjusted Performance

Weakest

Over the last 90 days Neuropace has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in September 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Cytek Biosciences

Risk-Adjusted Performance

Fair

Compared to the overall equity markets, risk-adjusted returns on investments in Cytek Biosciences are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain forward-looking signals, Cytek Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Neuropace and Cytek Biosciences

The main advantage of trading using opposite Neuropace and Cytek Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Cytek Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytek Biosciences will offset losses from the drop in Cytek Biosciences' long position.

The idea behind Neuropace and Cytek Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.